New: NCI-funded clinical trial search
Mednet Logo
CommunityEndocrinology

How do you counsel patients on the risk of non-arteritic anterior ischemic optic neuropathy (NAION) with use of GLP 1 R agonist therapy?

DeParis et al., PMID 42132708
Community PollStarted

How often do you discuss NAION risk when counseling patients about GLP-1 receptor agonist therapy?

13 physicians have voted

Join Mednetto vote and see how they answered.

1 Answer
Mednet MemberInvited Expert
Endocrinology · UNC
Answered on

I counsel patients on the risk of NAION with GLP-1RA therapy as follows: NAION is a rare condition that can cause blindness, usually just in one eye. It occurs in less than 1 in 10,000 people. It is unclear whether the GLP-1 drugs actually cause NAION, but they might. If they do, the best evidence i...

Join for free or sign in to see the full answer